A Phase II Study of Nemvaleukin Alfa in People with Cutaneous Melanoma or Mucosal Melanoma
Source: Memorial Sloan Kettering Cancer Center, July 2022
Full Title
A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients with Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy – ARTISTRY-6
Purpose
The purpose of this study is to assess the safety and effectiveness of the investigational immunotherapy drug nemvaleukin alfa in people with inoperable or metastatic cutaneous (skin) melanoma or mucosal melanoma (melanoma that begins in the mucus membranes that line various parts of the body). Nemvaleukin alfa works by attaching to an immune system protein called interleukin 2 and triggering an increase in the number of immune cells. By helping to increase immune cells, nemvaleukin alfa may boost the body’s natural defenses against cancer.